910381-19-0

Usage

Classification

Designer drug, analog of α-methyltryptamine (αMT)

Chemical structure

Substituted phenethylamine and serotonin receptor agonist

Identification

First identified in 2018 as a component of synthetic drug formulations

Intended use

Sold as a psychedelic substance

Effects

Believed to have hallucinogenic and stimulating properties similar to αMT

Risks

Implicated in a number of intoxications and deaths

Knowledge gaps

Little known about pharmacology, toxicology, and long-term health effects due to status as a novel psychoactive substance.

Upstream product

• 576-16-9 5-fluorotryptamine 
• 1059175-54-0 tert-butyl N-[2-(5-fluoro-1H-indol-3-yl)ethyl]carbamate 
• 116176-92-2 5-fluoro-1-methyl-1H-indole 
• 399-52-0 5-fluoro-1H-indole 
• 441715-30-6 5-fluoro-1-methyl-1H-indole-3-carboxaldehyde 

Relevant academic research and scientific papers

FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERARY

The present invention provides novel fused bicyclic alkylene linked imidodicarbonimidic diamides. In particular, described herein are N-[2-(indol-3- yl)alkylene]-linked imidodicarbonimidic diamides and N-[2-(pyrrolopyridin-3- yl)alkylene]-linked imidodicarbonimidic diamides (compound of formula (I) or formula (II)), and uses therefor. The compounds of the present invention are believed to be organic cation transporter selective compounds, useful for the treatment of diseases and conditions caused by reduced activity of 5' adenosine monophosphate-activated protein kinase (AMPK).

CuCl2/TBHP-mediated direct chlorooxidation of indoles

CuCl2/TBHP-mediated direct chlorooxidation of indole derivatives under simple aerobic conditions was reported, leading to facile preparations of a range of 3,3-disubstituted 3-chlorooxindoles in good yields and selectivities.